Outcomes of First-Line Anti-PD-L1 Blockades Combined with Brain Radiotherapy (BRT) for Extensive-Stage SmallCell Lung Cancer (ES-SCLC) with Brain Metastases (BM)

被引：0
|
作者：
Tian, Y. [1 ]
Ma, J. [2 ]
Zhu, H. [3 ]
Yu, J. [3 ]
机构：
[1] Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China
[2] Peoples Hosp Leling, Dept Oncol, Leling, Peoples R China
[3] Shandong First Med Univ & Shandong Acad Med Sci, Dept Radiat Oncol, Shandong Canc Hosp & Inst, Jinan, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2022年 / 114卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2804
引用
收藏
页码：E360 / E360
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study
    Qin, Boyu
    Xin, Lingli
    Liang, Chen
    Li, Lingling
    Song, Qi
    Long, Yaping
    Zhang, Xiaoling
    Wang, Dan
    Shi, Weiwei
    Zhang, Jing
    Hu, Yi
    Yang, Bo
    Xiong, Qi
    BMC CANCER, 2024, 24 (01)
  • [22] Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study
    Boyu Qin
    Lingli Xin
    Chen Liang
    Lingling Li
    Qi Song
    Yaping Long
    Xiaoling Zhang
    Dan Wang
    Weiwei Shi
    Jing Zhang
    Yi Hu
    Bo Yang
    Qi Xiong
    BMC Cancer, 24
  • [23] COMPARATIVE EFFECTIVENESS MODELING OF AN ANTI-PD-1 ANTIBODY DRUG INTERVENTION FOR PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) IN THE US
    Ventura, N.
    VALUE IN HEALTH, 2024, 27 (06) : S153 - S153
  • [24] Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer
    Shaw, Jaime
    Pundole, Xerxes
    Balasubramanian, Akhila
    Anderson, Erik S.
    Pastel, Malaika
    Bebb, D. Gwyn
    Jiang, Tony
    Martinez, Pablo
    Ramalingam, Suresh S.
    Borghaei, Hossein
    ONCOLOGIST, 2024, 29 (12): : 1079 - 1089
  • [25] Updated safety and efficacy results of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) from a phase II trial
    Chen, Dawei
    Gao, Aiqin
    Huang, Wei
    Shao, Qian
    Meng, Xiangjiao
    Tang, Xiaoyong
    Zhang, Pinliang
    Hu, Xudong
    Zhang, Yan
    Guo, Jun
    Fu, Lei
    Zhao, Wei
    Zhao, Changhong
    Yuan, Jiajia
    Yu, Jinming
    Wang, Linlin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] KEYNOTE-B99: Phase II study of pembrolizumab plus investigational agents combined with chemotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC)
    Peled, N.
    Rodriguez-Abreu, D.
    Bordoni, R.
    Ellis, P. M.
    Hochmair, M.
    Mueller, V.
    Levchenko, E.
    Zhou, H.
    Zhao, B.
    Lara-Guerra, H.
    Ahn, M-J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1425 - S1425
  • [27] Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report
    Chen, Yuanbin
    Paz-Ares, Luis
    Reinmuth, Niels
    Garassino, Marina Chiara
    Statsenko, Galina
    Hochmair, Maximilian J.
    Oezgueroglu, Mustafa
    Verderame, Francesco
    Havel, Libor
    Losonczy, Gyoergy
    Conev, Nikolay, V
    Hotta, Katsuyuki
    Ji, Jun Ho
    Spencer, Stuart
    Dalvi, Tapashi
    Jiang, Haiyi
    Goldman, Jonathan W.
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 3 (06):
  • [28] Impower133: Updated Overall Survival (OS) Analysis of First-Line (1L) Atezolizumab (ATEZO) plus Carboplatin plus Etoposide in Extensive-Stage SCLC (ES-SCLC)
    Reck, Martin
    Liu, Stephen V.
    Mansfield, Aaron S.
    Mok, Tony
    Scherpereel, Arnaud
    Reinmuth, Niels
    Garassino, Marina C.
    De Castro Carpeno, Javier
    Califano, Raffaele
    Nishio, Makoto
    Orlandi, Francisco
    Alatorre Alexander, Jorge Arturo
    Leal, Ticiana
    Cheng, Ying
    Lee, Jong-Seok
    Lam, Sivuonthanh
    Mccleland, Mark
    Deng, Yu
    Phan, See
    Horn, Leora
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 233 - 233
  • [29] Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
    Kong, Tiandong
    Chen, Lu
    Zhao, Xiaoli
    Duan, Fangfang
    Zhou, Hanli
    Wang, Lei
    Liu, Danna
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1095 - 1105
  • [30] Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
    Tiandong Kong
    Lu Chen
    Xiaoli Zhao
    Fangfang Duan
    Hanli Zhou
    Lei Wang
    Danna Liu
    Investigational New Drugs, 2022, 40 : 1095 - 1105
12345